Table 3.
Adjusted HRs for 180-Day Mortality by AP
| Group | HR (95% CI) | P Valuea |
|---|---|---|
| Intention-to-treat analysis | ||
| No AP exposure | 1 [Reference] | NA |
| Haloperidol | 5.08 (3.16–8.16) | <.001 |
| Other typical AP | 1.82 (0.94–3.50) | .07 |
| Olanzapine | 2.79 (1.97–3.96) | <.001 |
| Quetiapine fumarate | 2.16 (1.88–2.48) | <.001 |
| Risperidone | 2.46 (1.94–3.12) | <.001 |
| Other atypical AP | 1.19 (0.60–2.37) | .62 |
| Exposure-only analysis | ||
| No AP exposure | 1 [Reference] | NA |
| Haloperidol | 4.80 (2.41–9.57) | <.001 |
| Other typical AP | 0.82 (0.35–1.88) | .63 |
| Olanzapine | 2.76 (1.58–4.84) | <.001 |
| Quetiapine | 1.93 (1.59–2.33) | <.001 |
| Risperidone | 2.62 (1.83–3.76) | <.001 |
| Other atypical AP | 1.14 (0.41–3.18) | .80 |
Abbreviations: AP, antipsychotic; HR, hazard ratio; NA, not applicable.
a
Obtained from testing for the significance of the covariate estimates obtained from the corresponding Cox proportional hazards regression model.